SWBI

FY2026 was a credible bounce-back year for Smith & Wesson: revenue rose 10.4% to $524M and net income jumped 37.7% to $18.5M ($0.41 diluted EPS), driven almost entirely by handguns (+18.8% to $394M, with 935k units shipped vs 798k). The MD&A attributes the gain to newly introduced products and lower promotional costs/excise taxes, partially offset by a 100bp tariff headwind and unfavorable fixed-cost absorption. Operating cash flow exploded to $114M (from ~$6M), and management used it to repay $60M on the revolver — total liabilities fell 27% to $136M and L/E sits at a clean 0.36x. The balance sheet is fine and the dividend ($23.2M paid) is covered by cash generation.

The problem is the through-cycle picture and the multiple. Look at the five-year revenue arc: $864M → $479M → $536M → $475M → $524M. FY26 is still 39% below the FY22 COVID/social-unrest peak, and management itself flags in Risk Factors that demand spikes during periods of 'heightened fears of crime and terrorism' or anticipated gun-control legislation, then softens — they explicitly call out that 'unified Republican control' has historically dampened demand due to 'a perceived lower risk of federal gun control legislation.' Long guns are confirming that softness, down 13% in FY26. Gross margin at 26.9% is essentially flat YoY but well below the 29.5% of FY24, and operating margin of just 5.6% with ROE of 4.9% does not justify a 39x P/E or 1.4x P/S on the current price.